Skip to main content

Table 1 Characteristics of patients included in the study

From: Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study

Age (years), mean (SD) 61.4 (10.8)
Male/Women (n) 19/8
BMI (kg/m²), mean (SD) 24.6 (3.2)
Body weight (kg), mean (SD) 64.9 (8.9)
HbA1c (%), mean (SD) 7.4 (1.0)
Fasting plasma glucose levels (mg/dL), mean (SD) 145.8 (35.9)
Duration of diabetes (years), mean (SD) 8.8 (7.6)
Alcohol consumption, % 36.0
Smoking, % 44.0
eGFR (mL/min/1.73 m2), mean (SD) 82.7 (21.1)
ACR (mg/gCr), mean (SD) 34.1 (54.6)
Systolic blood pressure (mmHg), mean (SD) 129.8 (8.0)
Diastolic blood pressure (mmHg), mean (SD) 79.7 (7.3)
LDLC(mg/dL), mean (SD) 120.5 (31.4)
HDLC (mg/dL) mean (SD) 53.2 (14.0)
TG (mg/dL), mean (SD) 134.3 (49.4)
Retinopathy, % 14.8
Neuropathy, % 31.8
Nephropathy, % 29.6
Cardiovascular diseases, % 3.7
Oral hypoglycemic agent N (%)*
α-glucosidase inhibitors 0
Sulfonylureas 8 (29.6)
Biguanides 16 (59.2)
Glinide 0
SGLT2 inhibitors 0
Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers 9 (33.3)
Statin 10 (37.0)
  1. SD standard deviation, BMI body mass index, eGFR estimated glomerular filtration rate, ACR albumin creatinine ratio, HbA1c hemoglobin A1c, LDLC low-density lipoprotein cholesterol, HDLC high-density lipoprotein cholesterol, TG triglyceride, cardiovascular diseases comprise angina pectoris, myocardial infarction, stroke, and arteriosclerosis obliterans; SGLT2 sodium glucose cotransporter 2
  2. * There is a case of duplicates